Biotechnology

GRAIL

Grail Study Shows MCED Test Reduces ER Visits and Late-Stage Cancer by 51%

GRAIL Reports Earnings and Revenue Beat Estimates

GRAIL Reports Strong Q1 2026 Earnings and Projects Yearly Growth

GRAIL released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 40.79 M (forecast USD 39.65 M), actual EPS USD -2.2929 (forecast USD -2.6571)

GRAIL to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 39.15 M, EPS USD -2.7628

Junction Collaborates with GRAIL to Promote Galleri® Multi-Cancer Early Detection Test

GRAIL released FY2025 Annual Earnings on February 19 After-Market EST, actual revenue USD 147.17 M (forecast USD 147.17 M), actual EPS USD -11.1104 (forecast USD -11.61)

GRAIL released FY2025 Q4 earnings on February 19 After-Market EST, actual revenue USD 43.6 M (forecast USD 43.58 M), actual EPS USD -2.4352 (forecast USD -2.7)

GRAIL announces LANDMARK NHS-GALLERI trial results

GRAIL to Release FY2025 Q4 Earnings on February 19 After-Market EST, Forecast Revenue USD 43.48 M, EPS USD -2.8725

NWF Advisory Services Inc. Buys GRAIL Inc. Shares

Grail Inc. CEO sells company stock

Grail Inc. CFO Reports Disposition of Common Stock

Creative Planning and other investors increase holdings in GRAIL stock

Illumina, Inc. Disposes of Grail Inc. Common Stock

Guggenheim Analyst Reiterates Buy Rating on GRAIL Inc

Morgan Stanley Maintains Hold Rating on GRAIL Inc

Profund Advisors LLC reduces holdings in GRAIL

Grail Inc. Filed a Prospectus Supplement Involving Resale of Shares

GRAIL released FY2025 Q3 earnings on November 12 After-Market EST, actual revenue USD 36.19 M (forecast USD 35.4 M), actual EPS USD -2.463 (forecast USD -3.4766)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

GRAL

ARKG

GRAIL (NASDAQ:GRAL) reports rising demand for its Galleri multi-cancer early detection test, despite recent NHS study headlines. CFO Aaron noted increased inquiries from physicians focused on clinical benefits. GRAIL is in ongoing discussions with NHS and has submitted its review package to the FDA, which is under review. The test is primarily self-pay, with growth driven by physician adoption and partnerships. GRAIL aims for broad access and reimbursement, with infrastructure to support over 1 million tests annually.

Market Beat

Ark Genomic Revolution ETF

Bank of America

Quest Diagnostics

Hims & Hers Health

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

LABU

SBIO

IDNA

Wesbanco Bank Inc. reduced its stake in GRAIL, Inc. (NASDAQ:GRAL) by 73% in Q4, now holding 12,000 shares after selling 32,500. Other investors like Farallon Capital and Bank of America increased their stakes significantly. Insider sales included President Joshua J. Ofman and CFO Aaron Freidin, who sold shares at around $49.92. Analyst ratings for GRAIL vary, with a consensus rating of "Hold" and a target price of $67.88. GRAIL shares opened at $61.64, with a market cap of $2.65 billion and a 12-month range of $29.95 to $118.84.

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Genomics Immunology and Healthcare ETF

WesBanco

Annaly Capital Mgmt

Sculptor Capital

Sun Capital Management Corp.

Nano Labs

Allianz SE

Allianz

Allianz Technology Trust PLC

The Vanguard Group, Inc.

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

Invesco

Zensho Holdings Co., Ltd.

Financial Street

Charter Hall Long WALE REIT

Mizuho Financial

Mizuho Financial Group, Inc.

Piper Sandler Cos

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Toronto Dominion Bank

Bank of Montreal

Canadian Imperial Bank Comm

Wesbanco Pref Shares 7.375 WSBC Perp 10/01/30

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

AmpliTech

Charter Hall Retail REIT

Charter Hall Group

Charter Hall Social Infrastructure REIT

GRAIL, Inc. $GRAL Shares Sold by Wesbanco Bank Inc.

Grail (NASDAQ: GRAL) shares rose 14% this week following positive first-quarter earnings and anticipation of upcoming trial results at the ASCO meeting. Despite this rise, the stock is down nearly 28% this year due to disappointing trial results from a 3-year study with the NHS. Sales volumes for its multi-cancer early detection test, Galleri, are growing, and the company is pursuing FDA approval. However, investors should remain cautious about potential risks and uncertainties surrounding the stock's future performance.

nasdaq

SPDR S&P Biotech

Here's Why Grail Shares Popped Higher This Week

GRAIL, Inc. (NASDAQ:GRAL) reported strong first-quarter results, with revenues of US$41m exceeding estimates by 4.2% and smaller-than-expected losses of US$2.29 per share. Analysts have updated their forecasts, projecting revenues of US$181.4m for 2026, indicating a 16% increase, while losses per share are expected to rise to US$10.72. The consensus price target remains at US$68.57, reflecting stable business performance. GRAIL's revenue growth is anticipated to slow but align with industry trends. Analysts express cautious optimism, noting no significant changes in loss forecasts or revenue estimates.

Simplywall

Health Care Select Sector SPDR

Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results

Earnings Watch

GRAIL | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 40.79 M

GRAIL, Inc. (NASDAQ:GRAL) shares surged 13.2% to $61.58 after reporting better-than-expected earnings, with EPS of ($2.29) surpassing estimates of ($2.76). Revenue reached $40.79 million, exceeding the $39.16 million forecast. Despite a negative net margin of 277.46%, analysts maintain a consensus rating of "Hold" with an average target price of $67.38. Insider sales included CFO Aaron Freidin and CEO Robert P. Ragusa, who sold significant shares. GRAIL focuses on early cancer detection through its Galleri™ test, leveraging advanced technologies.

Principal Financial

GRAIL (NASDAQ:GRAL) Shares Up 13.2% Following Earnings Beat

Assurant shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

Assurant

Assurant Pref Share AIZN 5.25 01/15/61

GRAIL, Inc. reported strong Q1 2026 results with revenue of $40.8 million, driven by over 56,000 Galleri tests sold. The company anticipates 22%-32% sales growth for the year, supported by new integrations with Epic Aura. Despite a net loss of $93.2 million, GRAIL remains optimistic about its market position and upcoming data from significant trials. The management reiterated guidance without updates, focusing on expanding physician adoption and health system engagement.

iShares US Medical Devices

iShares US Healthcare Providers

GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations

TD Cowen analyst Daniel Brennan has reiterated a Buy rating on GRAIL Inc, raising the price target to $69. This decision is based on strong first-quarter performance, robust uptake of the Galleri test, and a 50% growth in volume. Upcoming clinical and regulatory catalysts, including data releases at ASCO and positive feedback from oncologists, further support his optimistic outlook on the company's market potential and cash position.

Tip Ranks

Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69

GRAIL | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 40.79 M

GRAIL(GRAL.US)